Cencora, Inc. (NYSE:COR) Shares Sold by Vestor Capital LLC

by · The Cerbat Gem

Vestor Capital LLC decreased its position in shares of Cencora, Inc. (NYSE:COR – Free Report) by 99.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 528 shares of the company’s stock after selling 58,372 shares during the quarter. Vestor Capital LLC’s holdings in Cencora were worth $119,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Kingswood Wealth Advisors LLC purchased a new position in Cencora in the second quarter valued at $655,000. TD Asset Management Inc purchased a new position in shares of Cencora in the 1st quarter valued at about $95,313,000. LSV Asset Management acquired a new position in Cencora in the 1st quarter worth about $3,579,000. Lake Street Advisors Group LLC purchased a new position in Cencora during the first quarter worth approximately $836,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new position in Cencora during the first quarter worth approximately $15,632,000. 97.52% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on COR shares. JPMorgan Chase & Co. upped their target price on Cencora from $280.00 to $287.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 21st. Wells Fargo & Company increased their price objective on shares of Cencora from $236.00 to $249.00 and gave the company an “equal weight” rating in a report on Thursday, August 1st. StockNews.com cut shares of Cencora from a “strong-buy” rating to a “buy” rating in a research note on Friday, September 20th. Evercore ISI reduced their price target on shares of Cencora from $270.00 to $250.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. Finally, Leerink Partners lowered their price objective on Cencora from $277.00 to $275.00 and set an “outperform” rating on the stock in a report on Monday, October 7th. Three analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $259.44.

Get Our Latest Stock Report on Cencora

Cencora Trading Up 2.7 %

COR opened at $234.27 on Monday. The firm has a market capitalization of $46.16 billion, a price-to-earnings ratio of 25.44, a price-to-earnings-growth ratio of 1.45 and a beta of 0.44. The company’s 50 day simple moving average is $231.39 and its two-hundred day simple moving average is $230.60. Cencora, Inc. has a 1-year low of $184.00 and a 1-year high of $247.66. The company has a debt-to-equity ratio of 3.93, a current ratio of 0.89 and a quick ratio of 0.55.

Insider Activity at Cencora

In other Cencora news, Chairman Steven H. Collis sold 21,509 shares of the business’s stock in a transaction on Tuesday, October 22nd. The stock was sold at an average price of $235.80, for a total transaction of $5,071,822.20. Following the transaction, the chairman now owns 285,088 shares of the company’s stock, valued at approximately $67,223,750.40. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, Chairman Steven H. Collis sold 21,509 shares of Cencora stock in a transaction on Tuesday, October 22nd. The stock was sold at an average price of $235.80, for a total transaction of $5,071,822.20. Following the transaction, the chairman now owns 285,088 shares in the company, valued at $67,223,750.40. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Silvana Battaglia sold 1,473 shares of the company’s stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $242.69, for a total transaction of $357,482.37. Following the completion of the sale, the executive vice president now directly owns 10,948 shares of the company’s stock, valued at $2,656,970.12. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 15.80% of the company’s stock.

Cencora Profile

(Free Report)

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.

See Also